Expansion Opportunities Knight Therapeutics operates across Canada and 10 Latin American countries, with recent product launches in Mexico such as TAVALISSE, and a growing portfolio including Minjuvi. This presents cross-border sales opportunities for in-licensing, distribution partnerships, and in-market commercialization support in multiple regions.

Revenue Momentum With reported revenue in the mid to high hundreds of millions and a 69% year-over-year Q1 revenue growth, Knight is demonstrating strong sales velocity. This suggests potential for expanding product penetration, tiered pricing strategies, and accelerated market access efforts for high-demand therapies.

Strategic Partnerships Active collaborations include a revolving credit facility with National Bank of Canada and prior in-kind funding investments, indicating openness to financing partnerships, co-promotion, and strategic alliances that can unlock further market access and distribution scale.

Therapeutic Focus Knight’s portfolio spans specialty oncology and immune-mediated diseases with launches like TAVALISSE and Minjuvi in regional markets. This positions the company for sales opportunities in physician-focused channels, hospital networks, and specialty pharmacies targeting ITP and lymphoma indications.

Market Presence Headquartered in Montreal with operations in Canada and 10 Latin American countries and a sizable workforce, Knight has established regional commercial infrastructure. This enables rapid onboarding of new partners, localized market access initiatives, and efficient support for in-market launches.